Latest:
Dr Foote on the Ongoing Debate Over Upfront EGFR Inhibitor Use in CRC
Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jose Tinajero, PharmD, BCOP
Jose Tinajero, PharmD, BCOP is a bone marrow transplant and hematology clinical pharmacist at City of Hope in Duarte, California.
Latest:
Dr Tinajero on the Role of Pharmacists in Treatment Planning and Management in CML
Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.
Shirley D'Sa, MD, FRCP, FRCPath
Latest:
Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study
Dr. Shirley D’Sa highlights the 5.8-year follow-up results from the ASPEN long-term extension study, demonstrating the durable efficacy, deepening responses, and favorable safety profile of zanubrutinib in patients with Waldenström macroglobulinemia, including those with high-risk genetic mutations.
Susumu Hijioka, MD, PhD
Susumu Hijioka, MD, PhD, works in the Department of Hepatobiliary and Pancreatic Oncology at National Cancer Center, in Japan.
Latest:
Dr Hijoka on Updated Efficacy Data With Everolimus Plus Lanreotide in GEP-NETs
Susumu Hijioka, MD, PhD, discusses the efficacy of first-line everolimus plus lanreotide in patients with unresectable or recurrent GEP-NETs.
Asad Dean, MD
Asad Dean, MD, is a physician at Texas Oncology and an assistant professor in the Division of Hematology/Oncology at UT Southwestern Medical Center.
Latest:
The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD
Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.
Natalia Neparidze, MD
Latest:
Bispecific Antibodies for the Treatment of RRMM in the Post CAR T Setting
Panelists discuss how the transition from chimeric antigen receptor T-cell therapy (CAR T) to bispecific antibodies depends on disease progression and clinical status, with the choice of bispecific antibody being guided by prior therapy and target antigen, preferring B-cell maturation antigen (BCMA) bispecifics for BCMA-exposed patients and GPRC5D bispecifics for those with BCMA-relapsed disease.
M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP
Latest:
Dr Habib on Developments in Palliative Care For Patients With Cancer
M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP, discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.